Madrigal Pharma's liver drug succeeds in study, shares soar

(Reuters) - Madrigal Pharmaceuticals Inc's lead experimental drug achieved the main goal of reducing liver fat in patients with fatty liver disease in a mid-stage study, sending its shares surging 66 percent in premarket trading on Thursday.